Isofol Medical AB (SE:ISOFOL)
:ISOFOL
Top Page
Isofol Medical AB
(ISOFOL)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr0.63
▼(-12.92% Downside)
Action:ReiteratedDate:02/27/26
The score is primarily constrained by weak financial performance—no recent revenue, ongoing losses, and continued cash burn—despite low leverage and improved burn versus earlier years. Technicals are moderately positive with price above key moving averages and supportive momentum, but valuation remains pressured due to unprofitability and no dividend data.
Positive Factors
Low leverage / no debt
A debt-free balance sheet materially reduces financing risk and interest burdens for a pre-commercial biotech. This gives management optionality to prioritize clinical development and partnering discussions without immediate debt-servicing constraints, preserving flexibility during pivotal trials.
Negative Factors
No recent revenue
The collapse to zero reported revenue demonstrates the company remains fully pre-commercial, eliminating internal cash generation to fund R&D or operations. Persistent absence of product sales increases reliance on external capital or partnering and raises dilution and execution risk over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage / no debt
A debt-free balance sheet materially reduces financing risk and interest burdens for a pre-commercial biotech. This gives management optionality to prioritize clinical development and partnering discussions without immediate debt-servicing constraints, preserving flexibility during pivotal trials.
Read all positive factors
Isofol Medical AB (ISOFOL) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr183.14M
Dividend YieldN/A
Average Volume (3M)501.89K
Price to Earnings (P/E)―
Beta (1Y)0.57
Revenue GrowthN/A
EPS Growth-34.02%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.05
Shares Outstanding281,107,240
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.2
Revenue Forecast (FY)N/A
Isofol Medical AB Business Overview & Revenue Model
Company Description
Isofol Medical AB (publ), a clinical stage biotech company, develops, commercializes, and sells oncology drugs in Sweden and internationally. The company develops arfolitixorin, which is in phase 3 clinical trial for the treatment of advanced colo...
How the Company Makes Money
null...
Isofol Medical AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 721.00K | 12.80M | 22.41M |
| Gross Profit | 0.00 | -38.73M | -34.41M | -165.71M | -174.31M |
| EBITDA | -54.76M | -47.21M | -37.02M | -159.73M | -198.49M |
| Net Income | -54.17M | -43.49M | -37.07M | -159.79M | -200.25M |
Balance Sheet | |||||
| Total Assets | 129.40M | 98.42M | 140.60M | 213.46M | 401.36M |
| Cash, Cash Equivalents and Short-Term Investments | 126.99M | 96.16M | 138.15M | 190.58M | 379.45M |
| Total Debt | 0.00 | 0.00 | 0.00 | 3.95M | 1.65M |
| Total Liabilities | 21.52M | 20.47M | 19.16M | 54.99M | 83.13M |
| Stockholders Equity | 107.87M | 77.94M | 121.43M | 158.48M | 318.23M |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -41.99M | -52.54M | -190.97M | -188.43M |
| Operating Cash Flow | -51.94M | -41.99M | -52.54M | -190.97M | -188.43M |
| Investing Cash Flow | 0.00 | 0.00 | 101.00K | 0.00 | 0.00 |
| Financing Cash Flow | 84.07M | 0.00 | 0.00 | 23.00K | 450.48M |
Isofol Medical AB Technical Analysis
Negative
0.72
Price Trends
0.66
Negative
0.69
Negative
0.77
Negative
Market Momentum
>-0.01
Positive
47.18
Neutral
39.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ISOFOL, the sentiment is Negative. The current price of 0.72 is above the 20-day moving average (MA) of 0.67, above the 50-day MA of 0.66, and below the 200-day MA of 0.77, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.18 is Neutral, neither overbought nor oversold. The STOCH value of 39.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ISOFOL.
Isofol Medical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr183.14M | -3.65 | -51.35% | ― | ― | -34.02% | |
45 Neutral | kr116.25M | -1.66 | -1291.15% | ― | ― | 28.54% | |
43 Neutral | kr129.62M | -1.72 | -199.86% | ― | 69.03% | 23.10% | |
43 Neutral | kr38.07M | -1.03 | -457.91% | ― | ― | -19.35% | |
41 Neutral | kr205.84M | -4.03 | ― | ― | -7.68% | 17.93% |
* Healthcare Sector Average
SE:ISOFOL
Isofol Medical AB
0.65
-1.04
-61.57%
SE:XINT
Xintela AB
0.24
-0.19
-44.29%
SE:IRLAB.A
IRLAB Therapeutics AB Class A
1.53
-6.44
-80.85%
SE:MODTX
Modus Therapeutics Holding AB
0.31
-0.18
-36.38%
SE:ACTI
Active Biotech AB
0.04
-0.03
-39.73%
SE:BIOWKS
Bio-Works Technologies AB
3.51
2.07
143.41%
Isofol Medical AB Corporate Events
Isofol Extends Arfolitixorin Rights Into Autism While Keeping Cancer Focus
Mar 18, 2026
Isofol Medical has expanded its global exclusive license for its lead candidate arfolitixorin to cover development and commercialization in autism spectrum disorder, specifically targeting patients with cerebral folate deficiency, a subgroup belie...
Isofol Sets TO1 Warrant Price and Exercise Window, Targets SEK 19 Million Raise
Mar 13, 2026
Isofol Medical has set the subscription price for its series TO1 warrants at SEK 0.48 per share, equal to 70 percent of the recent volume-weighted average share price, with an exercise window running from 16 to 30 March 2026. Full exercise of the ...
Isofol Secures Stakeholder Support Covering 42% of Upcoming TO1 Warrant Exercise
Mar 11, 2026
Isofol Medical has secured a top guarantee commitment from major shareholder Solasia Pharma and non-binding letters of intent from other large shareholders, its board and management to support the upcoming exercise of series TO1 warrants. Together...
Isofol to Add Major Shareholder Christian Haglund to Expanded Board
Mar 9, 2026
Isofol’s nomination committee has proposed the re-election of all current board members and the appointment of major shareholder Christian Haglund as a new director at the company’s annual general meeting on May 19, 2026. The proposal ...
Isofol to Showcase Cancer Drug Candidate at Key March Investor Events
Mar 3, 2026
Isofol Medical AB, listed on Nasdaq Stockholm, develops arfolitixorin, a proprietary folate-based drug candidate intended to boost the effectiveness of established cancer therapies, particularly in colorectal cancer. The company is running a phase...
Isofol Reports Strong Early Data for Arfolitixorin in Difficult-to-Treat Colorectal Cancer
Feb 24, 2026
Isofol Medical has reported encouraging interim data from its ongoing phase Ib/II study of arfolitixorin in RAS-mutated metastatic colorectal cancer, an especially hard-to-treat patient group. Conducted initially at Charité – Universit&...
Isofol strengthens arfolitixorin program with new EU patent and advancing trials
Feb 18, 2026
Isofol Medical AB continued development of its lead cancer drug candidate arfolitixorin during the fourth quarter of 2025, advancing a phase Ib/II study in metastatic colorectal cancer with dose escalation up to 300 mg/m² and planning a phase...
Isofol Showcases Arfolitixorin Trial Design at ASCO GI as Phase Ib/II Study Advances
Jan 9, 2026
Isofol Medical AB will participate in the ASCO GI Cancer Symposium in San Francisco, where it will present a Trial in Progress abstract outlining the design and recruitment status of its ongoing phase Ib/II study of arfolitixorin in metastatic col...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.